Aktienanalyse zu ALX Oncology Holdings Inc (ALXO)ALXOALX Oncology Holdings Inc

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, ALX Oncology Holdings Inc is trading at $2, with a year-to-date change of +73.91%. However, the company has reported significant losses, with a net income of -$17,927,000 in Q1 2026 and an EPS of -0.17, indicating ongoing financial challenges. The positive aspect is its sufficient cash reserves of $153.4 million, which can fund operations through mid-2028, providing some stability. The main risk is the negative earnings trend, as the company has consistently reported losses, with a forward P/E of 0 and a price-to-sales ratio of 0, suggesting that the stock is not generating revenue relative to its price.